Starr, P. (2015). Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL. Am Health Drug Benefits.
Citação norma ChicagoStarr, Phoebe. "Adding Ibrutinib to Standard Therapy Reduces Disease Progression By 80% in Previously Treated Patients With CLL." Am Health Drug Benefits 2015.
Citação norma MLAStarr, Phoebe. "Adding Ibrutinib to Standard Therapy Reduces Disease Progression By 80% in Previously Treated Patients With CLL." Am Health Drug Benefits 2015.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.